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Triple-negative breast cancers (TNBCs) are aggressive tumors with poor prognosis compared to other breast cancer subtypes.
The evidence linking TNBC with the metabolic syndrome, which consists of central obesity, insulin resistance, impaired glucose
tolerance, dyslipidemia, and hypertension, has emerged from clinical studies and experiments using cell lines and mouse models.
Epidemiological studies have associated abdominal obesity with increased incidence of TNBC. Additionally, insulin resistance,
dyslipidemia, and hypertension are associated with increased incidence of breast cancer across all subtypes. The insulin-leptin-
adiponectin axis has been implicated mechanistically in breast cancer tumorigenesis. Speciﬁcally, increased leptin and decreased
adiponectin levels disrupt homeostatic signaling pathways involved in cell proliferation, survival, cell-cycle regulation, and
angiogenesis. Insulin, insulin-like growth factor I (IGF-I), and epidermal growth factor receptor (EGFR) may mediate interactions
between these two hormones. Further research will facilitate the development of targeted therapeutics and programs to modify
lifestyle factors to modulate the insulin-leptin-adiponectin axis for TNBC.
1.Introduction
Triple-negative breast cancers (TNBCs) lack expression of
the steroid receptors estrogen (ER) and progesterone (PR)
and the tyrosine kinase human epidermal growth factor
receptor 2 (HER-2). Therefore, TNBCs are a diagnosis of
exclusion, typically characterized by upregulation of cytok-
eratins 5, 14, and 17 and elevation of the epidermal
growth factor receptor (EGFR) [1–3]. Studies estimate that
approximately 15–20% of breast cancers meet these criteria
[4–6].Comparedtootherbreastcancersubtypes,TNBCsare
typicallyaggressive,invasive(ductal,medullary,ormetaplas-
tic), grade III tumors with high rates of mitotic division, of
which approximately half contain a high rate of p53 muta-
tions [7]. For these reasons, they account for a dispropor-
tionately high percentage of metastases, distant recurrence,
and death among patients with breast cancer. Metastases
in TNBCs are most common to visceral organs including
liver, lungs, and central nervous system. As a diagnosis
of exclusion, TNBC overlaps considerably with basal-like
breast cancer (BLBC) although diﬀerences between the two
subtypes exist, especially at a genetic level. Other molecular
subtypesdeﬁnedbygeneexpressionpatternsincludeluminal
A, luminal B, HER-2-enriched group, and claudin-low, all
of which may include TNBCs to some extent [8, 9]. TNCBs
are most common among premenopausal women, especially
those of African American descent [4–6, 10]. In addition,
TNBCs are common among patients with BRCA1 mutations
[11, 12].
Since the ﬁrst molecular characterization of TNBCs in
the literature in 2005, the topic has quickly emerged as an
active area of research [13]. While initial studies focused
on molecular and clinical characterizations of patients with
the diagnosis, more recent studies have identiﬁed subgroups
of patients with TNBC, proposed molecular mechanisms
thatmaycontributetotumorigenesis,andexploredpotential
therapeutic interventions for patients. In this paper, we
examine the connection between TNBC and the metabolic2 International Journal of Breast Cancer
syndrome, which consists of central obesity, insulin resis-
tance, impaired glucose tolerance, dyslipidemia, and hyper-
tension. Our analysis of the literature will encompass in
vitro and in vivo studies in cell lines and mouse models
of TNBC, respectively, as well as clinical studies examining
epidemiology and treatment of TNBC.
2. Risk Factors for TNBC
Obesity, which is associated with insulin resistance and
type 2 diabetes mellitus (DM), is an established risk factor
for cancer incidence. In a meta-analysis of 141 articles,
body mass index (BMI) was positively associated with an
increased incidence of postmenopausal breast cancer, along
with colon, endometrial, esophageal, gallbladder, pancreas,
renal, thyroid cancers, leukemia, multiple myeloma, and
non-Hodgkin’s lymphoma in women [14]. The results were
less clear, however, for premenopausal breast cancer as a pos-
itive association between obesity and premenopausal breast
cancer was found in Asia-Paciﬁc women (risk ratio (RR) =
1.16; 95% CI, 1.01–1.32), while inverse relations were
reported in North American women (RR = 0.91; 95% CI,
0.85–0.98)andEuropeanandAustralianwomen(RR = 0.89;
95% CI, 0.84–0.94) These ﬁndings suggest that diﬀerent
subpopulations of women possess diﬀerent risk factors for
breast cancer. It may also suggest that BMI is not an
ideal measure of adiposity. Instead, other measures such as
waist-to-hip ratio (WHR) or waist circumference, which are
speciﬁc measures of central or abdominal adiposity, may
be preferential to assess cancer risk. Two meta-analyses that
examined a correlation between elevated WHR and risk of
breast cancer in premenopausal women reported positive
associations [15, 16]. The study by Connolly et al. reported
thatelevatedWHRwasassociatedwitha79%(summaryrisk
(SR) = 1.79; 95% CI, 1.22–2.62) increased risk of breast
cancer for premenopausal women and a 50% (SR =
1.50; 95% CI, 1.10–2.04) increased risk for postmenopausal
women [15]. Similarly, the study by Harvie et al. reported
that small WHR was associated with a 37% decreased risk
(RR = 0.63, 95% CI, 0.45–0.88) in premenopausal women
only after adjusting for BMI [16]. The authors hypothesized
that general obesity may not modulate risk, but central
obesity increases risk in premenopausal women. In contrast,
the authors reported that general obesity and not central
obesity increased cancer risk in postmenopausal women.
This interesting result led the authors to hypothesize that
insulin resistance and insulin-like growth factors, which are
associated with central obesity, may play a larger role in
modifying breast cancer risk for premenopausal women,
while estrogen may play a greater role in postmenopausal
breast cancer [16].
While the link connecting obesity and incidence of all
types of breast cancers is well established, the data examining
obesity and TNBC are much less prevalent. In the Carolina
Breast Cancer Study, WHR was compared between the
highest (≥0.84) and lowest (<0.77) groups in relation to
BLBC [17]. Across all women, there was an increased risk
(odds ratio (OR) = 2.3; 95% CI, 1.4–3.6) for developing
BLBC with higher WHR. Premenopausal women (OR = 1.8;
95% CI, 1.0–3.4) and postmenopausal women (OR = 2.7;
95% CI, 1.3–5.4) with high WHR both had elevated risk
of developing breast cancer compared to the lowest WHR
group. Weight gain in women as reported since ﬁfth grade
was highest in African American women in this sample. In
contrast, no signiﬁcant trend was reported for BMI and risk
of breast cancer. A 2008 study examining 620 predominantly
white women in rural Appalachia, 117 of whom had
TNBC, reported a signiﬁcant association between obesity
and incidence of TNBC [18]. In this sample, approximately
50% of patients with TNBCs were obese as compared to 36%
of non-TNBCs. Obesity in this study was deﬁned as a BMI
≥30. The preponderance of evidence suggests an association
between TNBC and obesity when obesity is deﬁned as an
elevated WHR, but more contradictory evidence exists when
using BMI as a measure of obesity. Clearly, the conﬂicting
results warrant additional research. Future epidemiological
studieswouldbeneﬁtfrommeasurementofallthreereceptor
markers and studies that concurrently examine multiple
deﬁnitions of obesity.
A common corollary of metabolic syndrome, type 2 DM,
has been associated with increased risk of breast cancer.
A 2007 meta-analysis of twenty studies estimated a 20%
increased risk of breast cancer for women with type 2 DM
(RR = 1.20; 95% CI, 1.12–1.28) [19]. For TNBC, one
study reported a signiﬁcant relation with 58% of patients
with TNBC possessing a comorbid diagnosis of metabolic
syndrome compared to 37% of patients without TNBC in
a sample of 176 individuals using criteria of the National
Cholesterol Education Program and 52% compared to
34% using criteria of the American Association of Clinical
Endocrinologists [20]. In addition, a 2011 study reported a
75% increase in the risk of postmenopausal breast cancer
(RR = 1.75; 95% CI, 1.37–2.22) for women who were found
to have at least three of the four components of metabolic
syndrome [21]. However, the Carolina Breast Cancer Study
reported no elevated prevalence of type 2 DM in TNBC
compared to other breast cancer subtypes [17].
Recently, epidemiological studies have associated dys-
lipidemia and hypertension with breast cancer risk. In
a prospective study examining all-cancer incidence of
1,189,719 Korean men and women, Kitahara et al. reported
a positive association between total cholesterol and breast
cancer risk in women (hazard ratio (HR) = 1.17; 95%
CI, 1.03–1.33) [22]. The researchers compared individu-
als with total cholesterol ≥240mg/dL to individuals with
cholesterol <160mg/dL and adjusted for cigarette smoking,
alcohol consumption, BMI, fasting serum glucose, hyper-
tension, and physical activity. In addition, hypertension was
independently predictive of breast cancer risk in a sample
of 3,869 postmenopausal women with breast cancer as
compared to 4,082 controls (OR = 1.19; 95% CI, 1.07–
1.33) [21]. Another study reported a 23% increased risk of
breast cancer for hypertensive women [23]. However, after
adjustment of confounders including BMI, the elevated risk
was no longer signiﬁcant (HR = 1.14; 95% CI, 0.93–1.40).
Epidemiological studies suggest a positive association
between the metabolic syndrome as a whole, along withInternational Journal of Breast Cancer 3
many of its individual components, and breast cancer risk.
Themanyconfoundingvariablesthatmaymediatethiseﬀect
need to be considered in order to determine whether this is a
causativeeﬀect.Studieswouldbeneﬁtfrommulti-institution
designs to assess geographically diverse populations. Further
studies should also address how changes in components
of metabolic syndrome, such as weight, aﬀect incidence of
disease, and treatment outcomes after initial diagnosis of
TNBC. Larger sample sizes will determine whether sub-
populations of patients with TNBC (e.g., pre- versus post-
menopausal women) possess unique clinical and molecular
characteristics.
3. Risk of Recurrence and Mortalityin TNBC
In addition to exploring risk factors that inﬂuence inci-
dence of TNBC (primary prevention), it is also essential
to understand factors that inﬂuence recurrence of TNBC
(secondary prevention). Compared to other subtypes of
breastcancer,TNBCsaremoreoftendiagnosedasaggressive,
invasive, grade III, and lymph-node positive tumors [7].
These outcomes are predictive of increased morbidity and
mortality. In addition, TNBCs have a high rate of recurrence
with visceral metastases compared to other subtypes of
breast cancer, especially within the ﬁrst ﬁve years after
diagnosis [24]. After ﬁve years, the risk of recurrence drops
dramatically.
Obese patients with breast cancer have more frequent
recurrenceandworseprognosisascomparedtoleanpatients.
In a sample of 495,477 U.S. women, increasing BMI was
signiﬁcantly associated with increased death rates for breast
cancer [25]. As compared to the lowest BMI group (18.5–
24.9), there was an elevated risk of 34% for BMI of 25.0–29.9
(RR = 1.34; 95% CI, 1.23–1.46), 63% for BMI of 30.0–34.9
(RR = 1.63; 95% CI, 1.44–1.85), 70% for BMI of 35.0–39.9
(RR = 1.70; 95% CI, 1.33–2.17), and 112% for BMI ≥ 40.0
(RR = 2.12; 95% CI, 1.41–3.19) of dying of breast cancer.
Furthermore,inasampleof18,967patientsinDenmarkwith
early-stage breast cancer, BMI at diagnosis was correlated
with disease prognosis. Patients with BMI ≥ 30 kg/m2 had
a 46% higher risk of distant metastases (HR = 1.46; 95% CI,
1.11–1.92) after 10 years and 38% increased risk of mortality
from breast cancer (HR = 1.38; 95% CI, 1.11–1.71) ) as
comparedtopatientswithBMI<25kg/m2 [26].Theauthors
also suggested that adjuvant chemotherapy and endocrine
therapy were less eﬀective over time periods greater than 10
years for patients with BMI > 30 although it was unclear
whether this eﬀect was mediated by poor responsiveness
to treatment or diﬀerences in biology. Even though obese
patients were more likely to present with advanced tumors in
terms of size and spread to lymph nodes, obesity was still an
independent predictor after controlling for these con-
founders. A recent, single institution study examined BMI
in 418 patients treated for TNBC [27]. The study measured
BMI after diagnosis of TNBC and then counted the number
of recurrences and deaths. After controlling for clinically
signiﬁcant factors, no signiﬁcant relation was found between
BMI and overall survival (HR = 0.94; 95% CI, 0.54–1.64)
or recurrence-free survival (HR = 0.81; 95% CI, 0.49–
1.34). In a sample of 1,169 patients diagnosed with invasive
breast cancer, the relationship between general obesity and
response to neoadjuvant chemotherapy was examined [28].
When comparing overweight (BMI 25 to <30kg/m2)a n d
obese (BMI ≥ 30kg/m2) groups to the normal/underweight
group (BMI < 25), a signiﬁcant association was present for
pathologic complete response to neoadjuvant chemotherapy
(OR = 0.67; 95% CI, 0.45–0.99) in the normal/underweight
group. While high BMI was associated with worse overall
survival, no signiﬁcant eﬀects were seen for breast-cancer
speciﬁc or progression-free survival. Finally, although data
linking risk of recurrence and mortality in patients with
hypertension and TNBC are limited, a 2011 study retro-
spectively examined the use of beta blockers on prognosis
for patients with breast cancer [29]. After adjustment for a
number of covariates, patients with TNBC who were taking
betablockershadsigniﬁcantlyimprovedrelapse-freesurvival
(HR = 0.30; 95% CI, 0.10–0.87), and while overall survival
was improved (HR = 0.35; 95% CI, 0.12–1.00), it only
approached a signiﬁcance level (P = 0.05). Similar ﬁndings
were also reported for non-TNBC subtypes.
A number of epidemiological studies have suggested that
physical activity and weight loss are inversely related breast
cancer risk and recurrence. The Women’s Healthy Eating and
Living (WHEL) Study prospectively examined 1,490 women
with breast cancer [30]. The authors reported that perform-
ing exercise equivalent to walking 30min, six days per week,
and consuming ≥5 daily servings of fruits and vegetables
decreased mortality by 46% (HR = 0.56; 95% CI, 0.31–
0.98). While ER+ tumors were associated with decreased
mortality with these lifestyle interventions (P<0.05), no
signiﬁcant eﬀect was observed for ER−,P R − tumors (P =
0.40). To the best of our knowledge, the largest study to
date examining the link between physical activity and
invasive breast cancer was a meta-analysis of 12,108 patients,
which included six studies [31]. While physical activity prior
to diagnosis had no eﬀect on breast cancer deaths across
all patients, physical activity after diagnosis reduced breast
cancer deaths by 34% (HR = 0.66, 95% CI, 0.57–0.77) and
disease recurrence by 24% (HR = 0.76, 95% CI, 0.66–0.87).
Postdiagnosis exercise only provided signiﬁcant beneﬁts for
patients with BMI ≥ 25kg/m2. Interestingly, physical activity
after diagnosis reduced breast cancer deaths by 50% (HR =
0.50, 95% CI, 0.34–0.74) for ER+ tumors with no signiﬁcant
eﬀect for patients with ER− tumors. When looking at the
individual studies that composed the meta-analysis, the
studies that examined postdiagnosis physical activity were
prospective, observational, and questionnaire-based studies,
while those that examined prediagnosis physical activity had
case-controldesigns[32–37].Whilethedeﬁnitionofphysical
activity varied somewhat from study to study, the studies
generally deﬁned physical activity as moderate recreational
activity, and for the purpose of their analyses, the authors
combined these forms of exercise into metabolic equivalent
task (MET) hours per week. Examples of moderate physical
activity included walking, jogging, running, biking, swim-
ming, tennis, calisthenics/aerobics, and squash/racquetball.4 International Journal of Breast Cancer
One study included in the meta-analysis speciﬁcally exam-
ined the relation between risk reduction of breast cancer
and duration of exercise [32]. In a sample of 2,987 women
diagnosed with breast cancer, the number of hours an
individual exercised per week was categorized. Compared
to women who performed the equivalent of walking at an
average pace less than 3 MET-hours per week, there was
a nonsigniﬁcant 20% risk reduction of death from breast
cancer for 3 to 8.9 MET-hours per week (RR = 0.80; 95%
CI, 0.60–1.06), a signiﬁcant 50% risk reduction for 9 to 14.9
MET-hours per week (RR = 0.50; 95% CI, 0.31–0.82), 44%
risk reduction for 15 to 23.9 MET-hours per week (RR =
0.56; 95% CI, 0.38–0.84), and 40% risk reduction for 24
or more MET-hours per week (RR = 0.60; 95% CI, 0.40–
0.89).Thisstudy,however,didnotﬁndasigniﬁcanteﬀectfor
exercise, even for 9 or more MET-hours per week, for ER−,
PR− tumors.
These studies provide an insight on the role of physical
activity as a potentially beneﬁcial breast cancer treatment
that may be used in conjunction with existing radiation and
chemotherapy treatments [32–37]. Although studies explic-
itlytargetingpatientswithTNBChavenotbeenperformed,a
potential mechanism behind this link may be decreased con-
centrationsofestrogenviareductioninbodyfatordecreased
androgens via increase in globulins that bind testosterone
[38]. Improvements in insulin resistance or blood glu-
cose may also mediate this eﬀect.
In addition to exercise, two large randomized studies
have examined whether diet interventions are eﬀective in
reducing breast cancer recurrence and mortality [39, 40].
The Women’s Intervention Nutrition Study (WINS) exam-
ined 2,437 women with breast cancer [39]. The randomized
study involved a dietary intervention group with a goal of
reducing calories from fat to 15% without compromising
nutrition compared to control with median followup of 60
months. The intervention group had statistically lower fat
intake (P<0.001). When comparing relapse events between
the two groups, relapse was lower in the intervention group
as compared to the control group (HR = 0.76; 95% CI,
0.60–0.98, P = 0.077 for stratiﬁed log rank and P = 0.034
for adjusted Cox model analysis). The authors reported
a trend for a stronger eﬀect for dietary fat reduction for
hormone receptor-negative cancers (HR = 0.58; 95% CI,
0.37–0.91) compared to ER+ tumors (HR = 0.85; 95%
CI, 0.63–1.14), although no signiﬁcant eﬀect was found
(interaction test, P = 0.15). One of the criticisms of the
WINS study was the fact that the intervention group lost
about 6 pounds more than the control arm over the duration
of the study (P = 0.005). As a result, it was unclear whether
the outcomes were due to decreased weight or decreased fat
intake. Furthermore, the dietary intervention was relatively
strict, making it hard to implement in everyday practice. In
addition, the WHEL study evaluated the potential beneﬁt
of physical activity and a diet rich in vegetables and fruit
in breast cancer survivors [40]. The study included 3,088
women with early-stage breast cancer. The arm randomized
to a diet rich in vegetables, fruit, and ﬁber, but low in fat
did not have a signiﬁcantly lower mortality (HR = 0.91;
95% CI, 0.72–1.15) or a lower incidence of second invasive
breast cancer (HR = 0.96; 95% CI, 0.80–1.14) during a 7.3-
year follow-up period. In this study, the intervention and
comparison groups had an average weight diﬀerence of 1-kg
orlessbasedonmeasurementsatbaseline,1year,2or3years,
4y e a r s ,a n d6y e a r s .I na na n a l y s i so ft h ec o m p a r i s o ng r o u p
only, consuming ≥5 daily servings of fruits and vegetables
and performing exercise equivalent to walking 30min, six
days per week at baseline was associated with lower mortality
[30]. No eﬀect, however, was reported in the randomized
trial based on physical activity at baseline for additional
breast cancer events or all-cause mortality. These conﬂicting
ﬁndings warrant further research, especially to assess diet
interventions for patients with TNBC.
Alcohol consumption also appears to moderate recur-
rence and mortality for breast cancer survivors. In a recent
study of 1,897 individuals, consumption of three to four
alcoholic drinks or more per week was associated with a 35%
(HR = 1.35; 95% CI, 1.00–1.83) increased risk of breast
cancer recurrence and 51% (HR = 1.51; 95% CI, 1.00–
2.29) increased risk of death due to breast cancer [41]. No
diﬀerence was found between ER+ versus ER− subgroups
although the authors noted that this lack of eﬀect may have
been due to a small sample size of patients with ER− tumors.
Further studies will be important to assess whether diﬀerent
subtypes of breast cancer are aﬀected diﬀerently by diet and
alcohol in order to further probe the mechanism of these
eﬀects.
4. InsulinandTNBC
Insulin is implicated as a link between obesity and breast
cancer risk. In particular, upregulation of insulin has been
hypothesizedtodirectlyincreaseproliferationofbreasttissue
andbreastcancercells.A2009study,whichmeasuredinsulin
atbaseline andat1,3, and6yearsoffollowup,reported aHR
of 2.22 (95% CI, 1.39–3.53) for incidence of breast cancer
in postmenopausal women when comparing the highest
baseline insulin concentration group to the lowest group
[42]. Another study demonstrated that a high homeostatic
model assessment score, which is associated with serum
levels of insulin and glucose, was correlated with increased
breast cancer mortality in a sample of 527 women [43].
Samples were collected at a single time point, 30 months
postdiagnosis. Similarly, a 2011 study of 604 women in the
Health, Eating, Activity, and Lifestyle (HEAL) Study mea-
sured serum C-peptide, a marker of insulin secretion, three
years after diagnosis [44]. An increased C-peptide concen-
tration of 1ng/mL was associated with a 35% increased risk
of death from breast cancer (HR = 1.35; 95% CI, 1.02–
1.87). Collectively, these data suggest that hyperglycemia
and hyperinsulinemia are associated with poor prognosis
for patients with breast cancer. In contrast, a 2007 case-
control study examining blood samples in predominantly
premenopausal women reported that increased levels of
insulin and C-peptide were not risk factors for breast cancer
[45]. This study, however, did not examine ER−,P R −
tumors. A recent study by Erickson et al. examined type 2
DM and associated prognosis in patients with breast cancerInternational Journal of Breast Cancer 5
[46]. Baseline hemoglobin A1C (HbA1C) levels among
3,003 patients were examined for recurrence and all-cause
mortality. The authors reported a signiﬁcant increase in all-
cause mortality after adjustment for confounders for women
withHbA1C ≥7.0%ascomparedto<6.5%(HR = 2.35;95%
CI, 1.56–3.54).
The actions of insulin may also occur indirectly via
decreased availability of globulin and insulin-like growth
factor- (IGF-) binding proteins and increased blood con-
centration of testosterone, estrogens, or IGFs. Elevated con-
centrations of unbound estradiol and testosterone have been
associated with increased breast cancer risk in pre- and post-
menopausal women [47–50]. These compounds have been
proposed as molecular links between obesity and breast can-
cer risk. Insulin also inhibits sex hormone-binding globulin
(SHBG) production and increases the levels of IGF-I in
blood, which results in increased mitogenic activity [51].
This link is consistent with approximately 50% of breast
cancer tumors overexpressing IGF-I receptor [52]. A recent
laboratory study found that seven cell lines that serve as
models of TNBC expressed IGF receptors [53]. Surprisingly,
expression was at similar levels to ER+ cell lines even though
type I IGF receptor levels are increased by estrogen in ER+
cell lines. In all cases, IGF-I increased proliferation and
survival of the cancer cell lines.
Although studies have reported a positive association
between type 2 DM and breast cancer, a potential confound-
ing variable in establishing this relation is treatment regimen
[54]. Insulin has recently been implicated to have cancer
promoting eﬀects, while recent evidence suggests metformin
to have cancer protecting eﬀects in patients with type 2 DM
[55]. Most patients with type 2 DM are prescribed either
insulin or metformin. Insulin glargine use, especially when
prolonged, may increase the incidence of breast cancer. In
onestudy,thiseﬀectwasespeciallyprominentforindividuals
who had received insulin for an average of 5.6 years before
starting insulin glargine (HR = 2.7; 95% CI, 1.1–6.5) [56].
In contrast, metformin has been shown to inhibit prolif-
eration and colony formation of TNBC cells in vitro [57].
Further experiments extended these ﬁndings into in vivo
mice. Metformin resulted in decreased tumor growth if
injected in TNBC tumor xenograft mice and decreased
tumor incidence if added before injecting TNBC cells.
While the molecular mechanism of how metformin reduces
breast cancer incidence and survival is unclear, potential
mechanisms include (1) acting as a general growth inhibitor,
(2) reducing serum insulin levels, and (3) reducing body
weight [54, 57]. Interestingly, the drug only exhibited an
antiapoptotic eﬀect in TNBC cell lines, an eﬀect which was
not present for luminal A, B, and HER-2 subtypes [58].
Recently, observational studies were performed suggesting
that metformin reduces the risk of breast cancer in humans.
Inonestudy,metforminusewasassociatedwitha38%lower
incidence of ER+, PR+ tumors in postmenopausal women
with type 2 DM [59]. No signiﬁcant eﬀect was demonstrated
for ER−,P R − tumors, however, although the sample size
for TNBCs was limited. In addition, prospective studies
are under way on the role of metformin in breast cancer
recurrence. Further studies are necessary to determine
whether elevated levels of insulin and C-peptide are risk
factors for women with TNBC, as well as to elucidate the
mechanism behind this association.
5.LeptinandTNBC
Leptinistheproductoftheobesity(ob)geneandisprimarily
synthesized and secreted by adipose tissue, with increasing
adiposity associated with higher circulating leptin levels.
[60]. Leptin helps regulate food intake and metabolism via
its actions on the arcuate nucleus of the hypothalamus. It
is hypothesized that leptin resistance in obese individuals
may be analogous to insulin resistance in diabetics [61].
This resistance has been proposed to develop via impaired
transport of leptin across the blood brain barrier and cir-
cumventricular organs and leptin receptor signal attenuation
[62]. Clinical studies have reported a positive association
between circulating blood leptin and breast cancer risk with
particular elevation of mRNA expression in adipocytes in
close proximity to the tumor [63].
On a molecular level, it has been hypothesized that
elevated leptin expression in epithelial mammary cells may
promote tumorigenesis via mechanisms including cell pro-
liferation (aromatase, MAPK, STAT3, and cyclin D1), angio-
genesis (VEGF), apoptosis (p53 and caspase 9), cell-cycle
regulation (p21), and cell survival (Akt) in breast cancer
cell lines [64]. In TNBC cell lines, a study by Saxena et al.
reported that leptin directly increased activity of the IGF-I
receptor [65]. Similarly, IGF-I reciprocally increased activity
of the leptin receptor via phosphorylation. In addition,
bidirectional crosstalk between leptin and IGF-I upregulated
EGFR promoting proliferation and migration of TNBC cells.
The study further reported that using the EGFR inhibitors,
lapatinibanderlotinib,inaninvitromodelsystemformetas-
tasis after application of leptin and IGF-I reduced invasion
and migration of breast cancer cells [65]. Collectively, these
data suggest a possible therapeutic route for treatment of
TNBC with EGFR inhibitors, because up to 70% of TNBCs
overexpress EGFR [7]. In addition to leptin and IGF-I,
a 2011 study by Burga et al. reported another potential
mechanism for elevated levels of EGFR protein [66]. After
RNA knockdown of BRCA1 in mammary epithelial cells,
EGFR protein was upregulated due to transcriptional mod-
iﬁcation and posttranslational stabilization of EGFR. This is
important to our understanding of TNBCs, because BRCA1
mutations are highly correlated with TNBCs. Interestingly,
EGFR inhibition with erlotinib in female BRCA1 knockout
mice, in vivo, prevented or delayed development of ER−,b u t
not ER+ tumors. However, the treatment was not eﬀective in
shrinking the tumor after tumorigenesis [66].
A causal link between leptin and breast cancer is
supportedbyanimalstudiesinwhichobesemicethatoverex-
pressed transforming growth factor-alpha (TGF-α), but were
deﬁcient in leptin, did not develop mammary tumors, while
heterozygous and homozygous wild type leptin mice devel-
oped tumors in 50% and 67% of cases, respectively [67].
However, these ﬁndings were diﬃcult to interpret, because
leptin deﬁcient mice possessed limited mammary tissue.6 International Journal of Breast Cancer
Further studies in mouse models, in vivo, suggest a thera-
peutic potential for leptin receptor, antagonists. In a recent
study of 69 TNBC tumors, 92% of breast tumors expressed
leptin receptor and 86% expressed leptin [68]. In this study,
the peptide Allo-aca, a leptin receptor antagonist, extended
survival time by up to 80% in a TNBC mouse xenograft
model, in vivo. Clinical studies are needed to determine
whether leptin antagonists may hold promise as a therapy in
humans, especially in obese patients who overexpress leptin.
Clinical trials in humans are currently underway to test
the eﬃcacy of EGFR inhibitors in TNBC. These studies have
focused on using cetuximab, a humanized antiEGFR IgG1
antibody in conjunction with ixabepilone, cisplatin, carbo-
platin, or a taxane. (NCT00633464, NCT00463788, [69–
71]). In one study, 12 patients with metastatic TNBC were
treated with either paclitaxel or docetaxel with cetuximab
weekly [69]. Of the eleven patients assessable to followup,
nine (82%) exhibited decrease in size of metastasis, but
three (27%) developed brain metastasis during treatment
(133). Other studies by Carey et al. and O’Shaughnessy et
al. have reported therapeutic value of using EGFR inhibitors
in conjunction with other chemotherapy agents including
(1) carboplatin plus cetuximab and (2) irinotecan and
carboplatin, plus cetuximab [70, 71]. The study by Carey et
al. compared cetuximab alone to carboplatin plus cetuximab
in patients with TNBC metastases [70]. Of the 71 patients
who received both drugs, 13 (18%) responded to treatment
as compared to only 2 of 31 (6%) of patients who received
cetuximab alone. In addition, the preliminary results of
the randomized phase II study of metastatic patients with
TNBC by O’Shaughnessy et al. reported no improvement
in objective response rate (ORR), progression-free survival,
andoverallsurvivalacrossallpatientswithmetastaticdisease
when comparing cetuximab in conjunction with irinotecan
and carboplatin as compared to irinotecan and carboplatin
[71]. However, subset analysis of revealed that ORR was
increased in metastatic patients with TNBC when using all
three drugs (19 of 39; 49%) as compared to only irinotecan
and carboplatin (10 of 33; 30%). These ﬁndings may suggest
a therapeutic beneﬁt of using EGFR inhibitors for a subset of
patientswithTNBC.Largerexperimentalandcontrolgroups
and increased number of follow-up years will beneﬁt our
understanding of the potential for these treatments.
6. Adiponectinand TNBC
Adiponectin, a protein secreted exclusively by adipose tissue,
is an endogenous insulin sensitizer. Levels of adiponectin
are inversely correlated with obesity. In contrast to the pro-
carcinogenic eﬀects of leptin, adiponectin may possess anti-
carcinogenic eﬀects. After controlling for BMI, studies have
reported that women with increased adiponectin concentra-
tions possessed a 65% reduced risk for breast cancer [72–
74]. In another sample of 527 women diagnosed with stage
I–IIIA breast cancer, adiponectin levels above 15.5μg/mL
were associated with improved breast cancer survival
(HR = 0.39; 95% CI, 0.15–0.95) [43]. Interestingly, in a
2011 study by Oh et al. the authors reported prognostic
value of adipokines in ER−,P R − tumors but not ER+,
PR+ tumors (P for trend =0.027) [75]. Patients with low
adiponectin levels as deﬁned by the ﬁrst quartile in the study
had a signiﬁcantly increased likelihood of cancer recurrence
as compared to patients in the fourth quartile (HR = 2.82;
95% CI, 1.03–7.68). These results were signiﬁcant even
after adjustment for BMI and homeostasis model assessment
scores for insulin resistance. Serum leptin levels were not
correlated with diseased outcome in this study. Genetic data
also links adiponectin to breast cancer risk. We recently
evaluated the role of adiponectin pathway single nucleotide
polymorphisms (SNPs) in breast cancer risk. We performed
a case-control study on 733 breast cancer cases and 839
controls and genotyped 10 haplotype-tagging SNPs of
adiponectin (ADIPOQ) and the type I adiponectin receptor
(ADIPOR1)g e n e s[ 76]. We showed that two functional poly-
morphisms of ADIPOQ, and one functional polymorphism
which has been shown to alter mRNA levels of ADIPOR1
was signiﬁcantly associated with risk of breast cancer. When
categorizedbysignalingstatus,lowadiponectinsignalershad
a 6.56-fold increase in breast cancer risk (95% CI, 0.78–
54.89), and intermediate adiponectin signalers had a 4.16-
fold increase in risk (95% CI, 0.49–35.19) compared to
high signalers (P for trend =0.001). Although these data are
preliminary, they provide evidence for a signiﬁcant role for
adiponectin in predicting breast cancer risk.
The mechanisms underlying the association between
adiponectin and breast cancer risk have been studied by
several investigators. Components of the adiponectin signal-
ing pathway have been implicated in breast tumorigenesis.
More speciﬁcally, a number of compounds related to cell
proliferation (aromatase, MAPK, and cyclin D1), apoptosis
(Bcl2 and caspase 8), cell-cycle regulation (AMPK), and cell
survival (Akt) have been implicated to mediate tumorigen-
esis in breast cancer cell lines [64]. While adiponectin has
been shown to have an antiproliferative eﬀect on cell growth
in both ER+ and ER− cell lines, the dominant mechanisms
responsible for these eﬀects in ER+ and ER− cell lines
arelikelydiﬀerent[72].Forexample,inMCF-7cells,24hour
treatment with adiponectin resulted in an antiproliferative
eﬀect lasting up to 96 hours [77]. Whether adiponectin
induces cell apoptosis is controversial and depends on the
particular breast cancer cell line and the duration of the
adiponectin incubation period [64]. One study reported that
increased cleavage of poly (ADP-ribose) polymerase (PARP),
which serves as an early apoptotic biomarker, was only
detected in ER+ cell lines [78]. Other studies have reported
that adiponectin inhibits aromatase and estrogen receptor
activity, mechanisms which would primarily act on ER+
tumors [64]. Collectively, these data suggest that adiponectin
acts via multiple signaling pathways with diﬀerent mecha-
nisms predominating in ER+ and ER− cell lines.
Animal studies have demonstrated that overexpression
of adiponectin, both locally and systemically, reduces mam-
mary tumor size [79]. In contrast, reduced expression of
adiponectin accelerates tumor onset and progression [80].
The proposed mechanisms linking low adiponectin levels
andbreastcarcinogenesisare(1)interactionwithinsulin[60,
81], (2) interaction with leptin [64], (3) inhibition of TNF-αInternational Journal of Breast Cancer 7
Figure 1: The insulin-leptin-adiponectin axis and risk of TNBC. Schematic representation demonstrates interactions of components in
blood. After the compounds enter a normal breast cell, changes in proliferation, survival, cell-cycle regulation, and angiogenesis result in
tumorigenesis of either TNBC or non-TNBC. Potential interventions for TNBC, at diﬀerent levels, are included on the right.
in macrophages [82], (4) binding of ﬁbroblast growth factor
andplatelet-derived growthfactor-betapolypeptide [82],(5)
inhibition of nuclear factor κB[ 83], and (6) promotion
of angiogenesis [84]. Further research exploring the link
between adiponectin levels over time and breast cancer risk
is needed in order to elucidate dominant mechanisms in
diﬀerent breast cancer subtypes. Furthermore, monitoring
changes in adiponectin levels in conjunction with diﬀerent
pharmacological and/or behavioral modiﬁcations such as
diet or exercise in human patients may contribute to a better
understanding of its role in TNBC. Finally, treatments aimed
at increasing adiponectin levels should be explored for their
potential therapeutic and preventive beneﬁt in breast cancer.
7. Conclusions
Considerable evidence links the components of metabolic
syndrome, including central obesity, insulin resistance, glu-
cose intolerance, dyslipidemia, and hypertension, with the
diﬀerent breast cancer subtypes. Although data on the con-
nectionbetweenTNBCandthemetabolicsyndromearelim-
ited, several studies have provided evidence for this associa-
tion. Studies have reported an association between elevated
abdominal obesity, as deﬁned by a high WHR, and increased
incidence of TNBC, but the evidence for BMI is more
contradictory [17, 18]. In addition, while type 2 DM and
insulin resistance are associated with elevated breast cancer
incidence, early evidence suggests that TNBCs do not have
increased prevalence of type 2 DM compared to non-TNBCs
[17]. In terms of disease progression, obesity is associated
with worse prognosis and increased recurrence across all
breast cancer subtypes [25, 26, 28]. Hyperglycemia and
hyperinsulinemia have also recently been associated with
increased incidence and poor prognosis [42–44]. Addition-
ally, behavioral modiﬁcations including moderate physical
activity, a diet rich in fruits, vegetables, and micronutrients,
and reduced alcohol consumption show promise across all
breast cancer subtypes [32–37, 39, 41]. It remains to be
seen whether these alternative therapies may prove useful in
conjunction with chemotherapy for patients with TNBC.
Molecular mechanisms of how these components of
metabolic syndrome may mediate tumorigenesis and disease
progression have been proposed. Insulin may mediate breast
cancer risk via both direct and indirect eﬀects, resulting in
increased concentration of androgens and estrogens, along
with increased concentration of IGF-I [47–53]. Leptin and
adiponectin, which are both secreted by adipose tissue and
often by breast tumors, act via a number of downstream
signaling pathways involved in cell proliferation, apoptosis,
cell-cycle regulation, angiogenesis, and cell survival [64]. It is
likely that normal cells must maintain a ﬁne balance between8 International Journal of Breast Cancer
leptin and adiponectin in order to maintain proper cell
and tissue homeostasis, and the components of metabolic
syndrome appear to disrupt this balance by increasing leptin
and decreasing adiponectin levels [61, 62, 64]. In addition,
insulin,IGF-I,andEGFRmayplayapivotalroleinmediating
the potential interactions between these two hormones [65,
66].
We propose that components of the metabolic syndrome
and the insulin-leptin-adiponectin axis play a pivotal role
in the pathogenesis and progression of TNBC (Figure 1). At
present, treatments for TNBC are limited compared to other
subtypes of breast cancer, because these tumors are resistant
tohormonetherapyanddrugsthattargettheHER-2protein.
Clinical trials have shown eﬃcacy of treatments such as
chemotherapy, anti-EGFR drugs, antiangiogenic drugs, and
PARP inhibitors in the treatment of TNBC [7]. Lifestyle
factors including diet, reduced alcohol consumption, and
physical activity, which may modulate components of the
metabolic syndrome, may also play a pivotal role in decreas-
ing incidence and risk of recurrence of TNBC. Trials that
incorporate agents such as metformin or leptin antagonists
as well as other therapies that modify the insulin-leptin-
adiponectin axis may prove very beneﬁcial for prevention
and treatment of TNBC.
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